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Abstract
Background: An inactivated quadrivalent influenza vaccine (QIV) was recently licenced in the US as a
thimerosal-free formulation presented in a pre-filled syringe. A multidose presentation is preferred in some
settings due to reduced acquisition and cold storage costs. We assessed the immunogenicity and safety of a
thimerosal-containing QIV formulated using a new manufacturing process for presentation in multidose vials.
Methods: Two Phase III non-randomized studies separately evaluated inactivated trivalent influenza vaccine
(TIV; 2010–2011; historical control) and a QIV (2011–2012). The QIV contained the same strains as the TIV plus an
additional B strain. Both vaccines contained thimerosal to allow multidose presentation: this preservative was
added to the QIV during the final formulation step using a new process, whereas it was added to the TIV early in
the manufacturing process using an established method. The TIV study included 50 and 70 subjects aged 18–60
and >60 years, respectively; the QIV study included 56 subjects in each age stratum. Immunogenicity was assessed
using hemagglutination-inhibition (HI) assays. Reactogenicity was assessed during the 4-day post-vaccination
periods and unsolicited adverse events (AEs) were assessed during the 21-day post-vaccination periods.
Results: The TIV and QIV were immunogenic in both age strata. With the QIV and TIV respectively, the
seroconversion rates were 48.2–62.7% and 71.4–83.7% for influenza A, and 33.9–62.5% and 67.3–72.9% for influenza
B. With the QIV and TIV respectively, the seroprotection rates were 92.9–98.2% and 98.2–100% for influenza A, and
88.6–100% and 95.9–98.6% for influenza B. Pre-vaccination titers were higher in the QIV versus TIV study which
confounds a direct comparison and likely explains the lower seroconversion rates observed in the QIV study. There
were no safety concerns raised with TIV or QIV.
Conclusions: The thimerosal-containing QIV formulated using a new process was immunogenic, conforming to
regulatory acceptance criteria, with a reactogenicity and safety profile in line with the TIV manufactured using a
licensed process. These results support acceptability of a manufacturing process change in which the thimerosal
preservative is added at the point at which batches are filled into multidose vials.
Trial registration: These trials were registered at ClinicalTrials.gov: NCT01440387; NCT01153685.
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Background
Influenza is an important cause of outpatient medical
visits and worker absenteeism among healthy adults, and
elderly adults are particularly vulnerable to influenza-
related complications [1-5]. In many countries, annual
vaccination of elderly individuals against influenza is rec-
ommended to reduce the burden of influenza-related
disease. In the US, annual vaccination is recommended
for all individuals 6 months of age and older [6].
Seasonal vaccines have been trivalent, containing
strains representing influenza A subtypes H1N1 and
H3N2, and one influenza B strain, according to re-
commendations from the World Health Organization
(WHO) based on forecasts from their global surveillance
program. However, two antigenically distinct influenza B
lineages (B/Yamagata and B/Victoria) emerged globally
in humans in the early 1980s, and have co-circulated in
the US since 2000 [7]. During about half of the influenza
seasons in the past decade in the US and Europe, the
recommended TIV was mismatched for the predomin-
ant circulating influenza B lineage [7,8]. Because there is
limited cross-protection between the two influenza B
lineages, B-lineage mismatch can reduce vaccine effect-
iveness [9-11].
The need for a seasonal vaccine that provides protec-
tion against both B lineages has prompted the develop-
ment of quadrivalent vaccines containing a strain from
both the B/Yamagata and B/Victoria lineages, and in
2012, the WHO included in its recommendation for the
first time four strains for quadrivalent influenza vaccines
for use in the vaccine for the 2012–2013 influenza sea-
son in the Northern Hemisphere [12]. Several quadriva-
lent influenza vaccines are now licensed in the US
[13-16], including an inactivated vaccine manufactured
by GlaxoSmithKline Vaccines in Quebec Canada, which
has been shown to be immunogenic with an acceptable
safety profile in children and adults [17,18]. This inacti-
vated QIV is provided as a thimerosal-free formulation
in a single-dose pre-filled syringe; however, because a
multidose presentation is preferred in some clinical set-
tings due to reduced acquisition costs and reduced de-
mand on cold chain storage systems (i.e. multidose vials
need less space per dose than prefilled syringes), a multi-
dose presentation containing thimerosal was also being
developed [19].
This report describes two, Phase III, non-randomized
studies of adults and elderly adults conducted by the
same investigator in successive years at a single center in
Canada when the recommended strains for a TIV did
not change: the first study in 2010–2011 evaluated a TIV
in a multidose presentation made by an already licensed
manufacturing method wherein the thimerosal preserva-
tive was added early in the process (this study was used
as an historical control); the second study in 2011–2012,
evaluated a candidate formulation of a QIV made by a
new process for the production of thimerosal-free vac-
cine, in which thimerosal preservative was then added
during the final manufacturing step to batches to be
filled into multidose vials. As the process change could
have affected the immunogenicity of the product, we
conducted the current study. The rationale for reporting
these two studies together is to characterize the im-
munogenicity, reactogenicity, and safety of the QIV can-
didate formulation alongside that of the TIV to evaluate
the acceptability of the new manufacturing process par-
ticularly regarding the European Union Committee for
Medicinal Products for Human Use (CHMP) immuno-
genicity acceptance criteria.
Methods
Two, Phase III, non-randomized studies were conducted
to evaluate the immunogenicity, reactogenicity, and
safety of TIV and QIV in adults aged 18–60 years
and >60 years. Both studies were conducted at a single
center in Canada over consecutive influenza seasons.
TIV was assessed during the 2010–2011 season and QIV
during the 2011–2012 season; the QIV contained the
same strains as the TIV plus a B strain from the alter-
nate lineage. The aim was to describe immunogenicity
and safety in younger and older adults, and to observe
whether there were any major differences between the
TIV and QIV, to evaluate the acceptability of the new
manufacturing process (details below) particularly re-
garding the CHMP immunogenicity acceptance criteria.
Adults aged ≥18 years who were in stable health were
eligible to enrol in the studies. Women of child-bearing
potential were required to practice reliable contraception
for 30 days before and 2 months after vaccination. In
both studies, subjects were not eligible for inclusion if
they had: received any investigational product 30 days
before the study or if this was planned during the study;
received any influenza vaccine within 6 months before
the study or if this was planned during the study, or par-
ticipated in a TIV (Fluviral™ GlaxoSmithKline Vaccines)
registration study conducted at the same site in 2009–
2010 (exclusion criterion for TIV trial only); received
any vaccine within 30 days of the study or if this was
planned during the study; acute illness at enrolment or a
significant acute or chronic uncontrolled medical or psy-
chiatric illness; had been diagnosed with cancer within
3 years of the study; a history of demyelinating disease; a
history of or suspected allergy to any of the vaccine
components, or a history of severe adverse reactions to
influenza vaccination. Subjects were not eligible for
inclusion if they had acute, clinically significant pulmon-
ary, cardiovascular, hepatic or renal functional abnor-
mality, or insulin-dependent diabetes mellitus. Subjects
with chronic illness not listed in the exclusion criteria
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were eligible for inclusion if the illness was stable and
controlled.
The study protocols, informed consent and other
information requiring pre-approval were reviewed and
approved by Institutional Review Boards (Institutional
Review Board Services and Optimum Ethics Review
Board) in accordance with Canadian regulatory require-
ments. The studies were conducted in accordance with
Good Clinical Practice, the principles of the Declaration
of Helsinki, and all regulatory requirements, including
Canadian requirements. All subjects gave informed writ-
ten consent.
Vaccines
The TIV was an inactivated trivalent, split-virion in-
fluenza vaccine (Fluviral™; GlaxoSmithKline Vaccines)
containing the WHO recommended strains for the
2010–2011 season in the Northern hemisphere: 15 μg
hemagglutinin antigen (HA) each of A/California/7/2009
NYMC X-179A (H1N1), A/Victoria/210/2009 NYMC
X-187 H3N2 (an A/Perth/16/2009 (H3N2)-like virus),
and B/Brisbane/60/2008 (Victoria lineage). The TIV was
manufactured with a process containing thimerosal,
which was added to the inactivation and splitting steps
of the process. During the formulation step, the thimero-
sal concentration was adjusted to reach a concentration
of 100 μg/mL. The TIV was presented in 5.0 mL multi-
dose vials containing 10 doses (0.5 ml) of vaccine.
The QIV was an inactivated quadrivalent, split-virion
influenza vaccine (FluLaval™ Quadrivalent; GlaxoS-
mithKline Vaccines) containing the WHO recommended
strains for the 2011–2012 season in the Northern hemi-
sphere, which were the same as those for the previous
season (as contained in the aforementioned TIV), plus
an additional B strain, which was B/Florida/04/2006
(Yamagata lineage). The QIV contained 15 μg HA of
each strain. The QIV was manufactured using a new thi-
merosal free process, which involved the inactivation
and splitting of the viruses in absence of thimerosal. Thi-
merosal was added at the formulation step to reach a
concentration of 100 μg/mL as a preservative to those
batches to be filled into multidose vials. Exclusively for
this study, the thimerosal-containing QIV was presented
in pre-filled syringes containing one 0.5 mL dose of
vaccine.
Both vaccines were manufactured by GlaxoSmithKline
Vaccines, in Quebec, Canada. Subjects received one
0.5 mL dose of TIV or QIV administered intramuscu-
larly in the deltoid region of the non-dominant arm.
Each study was open-label.
Immunogenicity
In the TIV and QIV studies, the primary objective was to
assess the humoral immune responses against each
vaccine strain 21 days after vaccination in subjects aged
18–60 years and >60 years. Serum samples for antibody
testing were obtained on Day 0 before vaccination, and
21 days after vaccination. Antibody responses were
assessed using a serum hemagglutination inhibition (HI)
assay as previously described [20].
HI antibody responses were described as the anti-log
of the arithmetic mean of the log-10 transformed inverse
geometric mean titre (GMT), seroprotection rate (SPR;
proportion with post-vaccination titer ≥1:40), serocon-
version rate (SCR; proportion with pre-vaccination anti-
body titer <1:10 and with post-vaccination titer of ≥1:40,
or pre-vaccination titer of ≥1:10 and a ≥4-fold post-
vaccination increase in titer), and mean geometric
increase (MGI; geometric mean of the ratio between
post-vaccination and pre-vaccination reciprocal HI
titers). Subjects with HI antibody titers of ≥1:10 were
considered to be seropositive.
Reactogenicity and safety
The secondary objectives were to assess reactogenicity
and safety.
Solicited injection site and general adverse events were
assessed during the 4 day post-vaccination period. Sub-
jects used diary cards to record solicited injection site
symptoms (pain, redness, and swelling/induration) and
general symptoms (chest tightness or difficulty in
breathing, chills, cough, fatigue, headache, joint pain,
muscle pain, red eyes, sore throat/hoarseness/pain on
swallowing, swelling of the face, fever), and rated each
symptom for severity. Injection-site events were consid-
ered to be vaccine-related, and investigators provided
causality assessments for general symptoms.
Unsolicited adverse events (AEs) and serious adverse
events (SAEs) were assessed from Day 0 to 21 days post-
vaccination. All AEs were graded for intensity and
recorded according to the Medical Dictionary for Regu-
latory Activities (MedDRA) classification. Investigators
provided causality assessments for unsolicited events.
Analyses
The sample sizes in the TIV and QIV studies were based
on the requirements for annual registration of influenza
vaccine in Canada and Europe which stipulate a mini-
mum of 50 subjects are needed in each age stratum.
In both studies, immunogenicity parameters were de-
scribed with an exact 95% confidence interval (CI). HI
immune responses were assessed according to the to the
European Union Committee for Medicinal Products for
Human Use (CHMP) licensure criteria: to fulfil the cri-
teria the point estimates for SCR needed to be >40%,
SPR >70%, and MGI >2.5 in the 18–60 years group, and
SCR >30%, SPR >60%, and MGI >2.0 in the >60 years
group [21].
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Exploratory analyses were conducted to assess
immunogenicity in each age stratum (18–60 years
and ≥60 years) according to influenza vaccination his-
tory. Immune responses were evaluated according to
received/did not receive seasonal influenza vaccine
during either the preceding three seasons (TIV study;
2009–2010, 2008–2009, 2007–2008) or the preceding
season (QIV study; 2010–2011).
The immunogenicity analyses were performed on the
per-protocol immunogenicity cohort including all eli-
gible subjects without protocol deviation who had sero-
logical data available at a given time point (Day 0, Day
21, or both). The frequency of solicited and unsolicited
AEs was tabulated with a 95% CI. Solicited and unsoli-




Subject flow and analysis groups are shown in Figure 1.
In the QIV study, 56 subjects were vaccinated in each
age strata, all of which completed the study; the mean
age in the 18–60 years group (younger group) was
40.9 years, and in the >60 years group (older group) was
68.6 years (Table 1). In the TIV study, 120 subjects were
enrolled and completed; in the TVC at vaccination, there
were 50 subjects in the 18–60 years group (younger
group), with a mean age of 34.8 years, and 70 subjects
aged >60 years group (older group), with a mean age of
66.6 years (Table 1). In the TIV study, in the younger age
group, 20 subjects (40%) and in the older group 44 sub-
jects (62.9%) had received seasonal influenza vaccine at
least once during the previous 3 seasons.
At baseline, GMTs were higher in the QIV study in
the younger group (45.3–130.4) and older group (23.2–
57.3) compared with the TIV study in the younger
(14.1–39.2) and older group (13.0–28.0).
In the TIV study, the first subject was enrolled on 9
July 2010 and the last study visit was on 31 July 2010.
In the QIV study, the first subject was enrolled on 30




Pre-vaccination seropositivity rates were >87.5% and >71.4%
in the younger and older age strata, respectively (Table 2).
The QIV was immunogenic in both age strata, and SPRs
and MGIs fulfilled CHMP licensure criteria in both age
groups against each vaccine strain (Table 2; Figures 2 and
3). SCRs fulfilled licensure criteria for all strains in the
older age group, and for the A strains in the younger
group. The SCR for B/Yamagata and B/Victoria fell below
the licensure threshold in the younger age group at
35.7% and 33.9%, respectively (Figure 3).
The exploratory analysis of immune response by age
and previous seasonal vaccination history showed that
previous vaccination reduced immune responses against
both B strains in subjects aged 18–60 years. In the youn-
ger age stratum, SCRs in subjects who had not been vac-
cinated against seasonal influenza during the previous
year fulfilled licensure criteria for all strains, but in those
who had been vaccinated, SCRs did not reach the licen-
sure threshold for A/H1N1 (35.7%), A/H3N1 (32.1%),
the Victoria lineage B strain (14.3%) or the Yamagata
lineage B strain (21.4%). In the older age stratum, im-
mune responses fulfilled all licensure criteria for each
strain regardless of vaccination history (Table 3).
Trivalent vaccine
Pre-vaccination seropositivity rates were higher for the B
strain than the A strains, particularly in the >60 years
group (Table 4). Post-vaccination GMTs were higher in
younger versus older subjects against A/H1N1 (390.1:
95% CI, 293.8–518.1 versus 142.1: 95% CI, 105.1–192.0,
respectively), but this was not observed for A/H3N2 or
the B strain (Table 4).
The TIV was immunogenic in both age strata, and
SCRs, SPRs, and MGIs fulfilled CHMP licensure criteria
in both age groups against each vaccine strain (Figures 2
and 3; Table 5). The exploratory analysis of immune re-
sponse by age and previous vaccine exposure showed







































Figure 1 Subject flow. QIV, inactivated quadrivalent influenza
vaccine. TIV, inactivated trivalent influenza vaccine
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within the previous three seasons did not have a major
effect on subsequent immune responses to the TIV
(Table 5). Antibody responses fulfilled licensure criteria
in both age strata regardless of previous vaccination his-
tory. In the younger group, the SPRs at Day 21 in those
with and without previous seasonal influenza vaccination
were 100% and 93.1–100%, respectively, and in the older
group were 93.2–100% and 80.8–96.2%, respectively.
However, there was a trend for lower immune responses
in the subjects who had received previous seasonal vac-
cine based on SCRs and MGIs. In the younger group,
the SCRs in those with and without previous seasonal
vaccination were 50.0–75.0% and 75.9–89.7%, respect-
ively, and in the older group were 61.4–79.5% and 73.1–
92.3%, respectively. In the younger group, the MGIs in
those with and without previous vaccination were 5.3–
Table 1 Demographic characteristics at baseline in the total vaccinated cohorts
TIV QIV
N = 120 N = 112
18–60 years >60 years 18–60 years >60 years
n = 50 n = 70 n = 56 n = 56
Mean age, years (SD; median; range) 34.8 66.6 40.9 68.6
(13.72; 28.0; 19.0–59.0) (4.73; 65.0; 61.0–81.0) (13.33; 39.5; 22.0–60.0) (4.72; 67.5; 61.0–82.0)
Male, n (%) 17 (34.0) 31 (44.3) 22 (39.3) 26 (46.4)
Female, n (%) 33 (66.0) 39 (55.7) 34 (60.7) 30 (53.6)
Ethnic origin, n (%)
White Caucasian/European heritage 47 (94.0) 69 (98.6) 54 (96.4) 56 (100)
Other 3 (6.0) 1 (1.4) 2 (3.6) 0
Seasonal influenza in at least 1 season
from previous 3 seasons
20 (40.0) 44 (62.9) 54 (96.4) 54 (96.4)
AS03-adjuvanted pandemic influenza
vaccine in the previous (2010–2009) season
26 (52.0) 33 (47.1) n/a n/a
TIV, inactivated trivalent influenza vaccine; QIV, inactivated quadrivalent influenza vaccine; SD, standard deviation.




n (%; 95% CI) value (95% CI) value (95% CI)
18–60 years >60 years 18–60 years >60 years 18–60 years >60 years
N = 56 N = 56 N = 56 N = 56 N = 56 N = 56
A/H1N1 Day 0 49 40 82.0 25.0 – –
(87.5; 75.9–94.8) (71.4; 57.8–82.7) (54.9–122.5) (17.3–36.0)
Day 21 56 55 392.5 223.5 4.8 8.9
(100; 93.6–100) (98.2; 90.4–100) (305.4–504.4) (157.0–318.1) (3.3–7.0) (5.8–13.7)
A/H3N2 Day 0 49 40 45.3 23.2 – –
(87.5; 75.9–94.8) (71.4; 57.8–82.7) (31.3–65.4) (16.4–32.8)
Day 21 56 55 215.4 160.1 4.8 6.9
(100; 93.6–100) (98.2; 90.4–100) (166.3–278.9) (115.7–221.4) (3.5–6.6) (4.7–10.1)
B strain (Victoria) Day 0 54 52 92.8 38.5 – –
(96.4; 87.7–99.6) (92.9; 82.7–98.0) (66.5–129.4) (28.3–52.4)
Day 21 56 56 318.0 237.8 3.4 6.2
(100; 93.6–100) (100; 93.6–100) (251.4–402.3) (179.7–314.9) (2.5–4.6) (4.3–8.8)
B strain (Yamagata) Day 0 56 54 130.4 57.3 – –
(100; 93.6–100) (96.4; 87.7–99.6) (92.8–183.2) (44.3–74.0)
Day 21 56 56 404.8 355.5 3.1 6.2
(100; 93.6–100) (100; 93.6–100) (323.1–507.2) (263.5–479.5) (2.4–4.0) (4.6–8.4)
QIV, inactivated quadrivalent influenza vaccine; Seropositive, titer ≥1:10; GMT, geometric mean titer; MGI, mean geometric increase defined as the geometric
mean of the ratio between pre-vaccination and post-vaccination reciprocal titers.
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B strain (Victoria)
Figure 2 Seroprotection rates 21 days after QIV (A) or TIV (B) in the per-protocol immunogenicity cohort. QIV, inactivated quadrivalent
influenza vaccine; TIV, inactivated trivalent influenza vaccine; Seroprotection rate defined as proportion with post-vaccination titer ≥1:40; European
Union Committee for Medicinal Products for Human Use (CHMP) licensure threshold for seroprotection rate: ≥70% in the 18–60 years group,
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Figure 3 Seroconversion rates 21 days after QIV (A) or TIV (B) in the per-protocol immunogenicity cohort. QIV, inactivated quadrivalent
influenza vaccine; TIV, inactivated trivalent influenza vaccine; Seroconversion rate defined as the proportion with antibody titer <1:10 at baseline
and with post-vaccination titer of ≥1:40, or pre-vaccination titer of ≥1:10 and a ≥4-fold post-vaccination increase in titer; European Union
Committee for Medicinal Products for Human Use (CHMP) licensure threshold for seroconversion: >40% in the 18–60 years group, and >30%
in the >60 years group [17].
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8.9 and 12.6–19.6, respectively. Reduced MGIs were par-
ticularly pronounced in the older group between those




Solicited adverse events during the 4-day post-vaccination
period are shown in Table 6. Pain was the most frequent
Table 3 Hemagglutination-inhibition antibody responses after QIV according to previous seasonal influenza






n/N (%; 95% CI) n/N (%; 95% CI) N; value (95% CI)
18–60 years >60 years 18–60 years >60 years 18–60 years >60 years
N = 28 N = 28 N = 28 N = 28 N = 28 N = 28
A/H1N1 Yes Day 0 25/28 16/28 – – – –
(89.3; 71.8–97.7) (57.1; 37.2–75.5)
Day 21 28/28 25/28 10/28 9/28 28; 3.1 28; 3.5
(100; 87.7–100) (89.3; 71.8–97.7) (35.7; 18.6–55.9) (32.1; 15.9–52.4) (2.0–4.9) (2.3–5.2)
No Day 0 19/28 10/28 – – – –
(67.9; 47.6–84.1) (35.7; 18.6–55.9)
Day 21 27/28 27/28 18/28 25/28 28; 7.4 28; 22.9
(96.4; 81.7–99.9) (96.4; 81.7–99.9) (64.3; 44.1–81.4) (89.3; 71.8–97.7) (4.1–13.3) (12.7–41.2)
A/H3N2 Yes Day 0 21/28 19/28 – – – –
(75.0; 55.1–89.3) (67.9; 47.6–84.1)
Day 21 27/28 26/28 9/28 13/28 28; 2.7 28; 3.4
(96.4; 81.7–99.9) (92.9; 76.5–99.1) (32.1; 15.9–52.4) (46.4; 27.5–66.1) (2.0–3.6) (2.5–4.7)
No Day 0 13/28 9/28 – – – –
(46.4; 27.5–66.1) (32.1; 15.9–52.4)
Day 21 27/28 27/28 18/28 22/28 28; 8.5 28; 13.8
(96.4; 81.7–99.9) (96.4; 81.7–99.9) (64.3; 44.1–81.4) (78.6; 59.0–91.7 (5.2–13.9) (7.4–25.6)
B strain (Victoria) Yes Day 0 26/28 17/28 – – – –
(92.9; 76.5–99.1) (60.7; 40.6–78.5)
Day 21 28/28 27/28 4/28 12/28 28; 2.4 28; 3.3
(100; 87.7–100) (96.4; 81.7–99.9) (14.3; 4.0–32.7) (42.9; 24.5–62.8) (1.7–3.3) (2.3–4.9)
No Day 0 21/28 14/28 – – – –
(75.0; 55.1–89.3) (50.0; 30.6–69.4)
Day 21 28/28 28/28 15/28 21/28 28; 4.9 28; 11.5
(100; 87.7–100) (100; 87.7–100) (53.6; 33.9–72.5) (75.0; 55.1–89.3) (3.0–7.9) (6.8–19.2)
B strain (Yamagata) Yes Day 0 27/28 24/28 – – – –
(96.4; 81.7–99.9) (85.7; 67.3–96.0)
Day 21 28/28 28/28 6/28 12/28 28; 2.1 28; 4.1
(100; 87.7–100) (100; 87.7–100) (21.4; 8.3–41.0) (42.9; 24.5–62.8) (1.6–2.7) (2.6–6.5)
No Day 0 21/28 21/28 – – – –
(75.0; 55.1–89.3) (75.0; 55.1–89.3)
Day 21 28/28 28/28 14/28 23/28 28; 4.6 28; 9.4
(100; 87.7–100) (100; 87.7–100) (50.0; 30.6–69.4) (82.1; 63.1–93.9) (3.1–6.9) (6.4–13.8)
†Received (yes) or did not receive (no) seasonal influenza vaccine during the preceding season (2010–2011); QIV, inactivated quadrivalent influenza vaccine; n/N,
number fulfilling definition of response/total number in group; SCR, seroconversion rate defined as the proportion with antibody titer <1:10 at baseline and with
post-vaccination titer of ≥1:40, or pre-vaccination titer of ≥1:10 and a ≥4-fold post-vaccination increase in titer; SPR, seroprotection rate defined as proportion with
post-vaccination titer ≥1:40; MGI, mean geometric increase defined as the geometric mean of the ratio between pre-vaccination and post-vaccination reciprocal
titers; Immune responses were assessed according to the to the European Union Committee for Medicinal Products for Human Use (CHMP) licensure criteria:
to fulfil the criteria the point estimates for SCR needed to be >40%, for SPR >70%, and MGI >2.5 in the 18–60 years group, and SCR >30%, for SPR >60%, and
MGI >2.0 in the >60 years group [21].
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solicited injection site event, and was much more fre-
quent in the younger (41/56; 73.2%) than the older group
(19/56; 33.9%). Other solicited injection site events were
infrequent in the younger (≤1.8%) and older groups
(≤3.6%). There were no Grade 3 injection site events. The
most frequent solicited general events in the younger
group were muscle pain (21/56; 37.5%), headache (11/56;
19.6%) and fatigue (10/56; 17.9%), and in the older group
was muscle pain (6/56; 10.7%). All general AEs reported
in both groups were considered by the investigator to be
related to vaccination. One subject in the older group re-
ported a Grade 3 event (fatigue).
During the 21-day post-vaccination period, in the
younger group, 13 (23.2%) subjects reported at least 1
unsolicited AE, of which none were Grade 3 or consid-
ered to be related to vaccination. In the older group, 12
(21.4%) subjects reported at least 1 unsolicited AE, of
which 1 was Grade 3 (arthralgia), and 1 (injection site
haemorrhage) was considered to be related to vaccin-
ation. There were no SAEs, death or withdrawals due to
AE/SAEs during the study.
Trivalent vaccine
Solicited adverse events during the 4-day post-vaccination
period are shown in Table 6. Pain was the most frequent
solicited injection site event, and was much more fre-
quent in the younger (41/50; 82.0%) than the older
stratum (18/69; 26.1%). There were no Grade 3 injection
site events, and only 3 reports of injection site events
other than pain. The most frequent solicited general
events in the younger group were muscle pain (17/50;
34.0%), fatigue (15/50; 30.0%) and headaches (13/50;
26.0%), and in the older group were fatigue (7/69; 10.1%),
muscle pain (6/69; 8.7%), and headaches (6/69; 8.7%).
During the 21-day post-vaccination period, a total of 16/
50 subjects in the younger group (32.0%) repo-rted at least
one unsolicited AE, which were most frequently nausea
(6.0%) and diarrhoea (6.0%); 8 (16.0%) subjects reported
AEs that were considered by the investigator to be related
to vaccination, which were abdominal pain, diarrhoea,
nausea, fatigue, injection site haematoma, injection site
pain, injection site paraesthesia, dizziness, headache, and
sedation. During the 21-day post-vaccination period, a
total of 17/70 (24.3%) subjects in the older group re-
ported at least one unsolicited AE, which was most fre-
quently headache (4.3%); 3 (4.3%) subjects reported AEs
that were considered by the investigator to be related to
vaccination, which were nausea, dizziness, and sinus
headache.
There were 2 SAEs (Crohn’s disease and nephritis
colic), which were both in the younger group and were
not considered to be related to vaccination. There were
no deaths during the study, and no withdrawals due to
AEs/SAEs.
Discussion
In this analysis of two, Phase III, non-randomized stud-
ies, there were no notable differences observed in the
immunogenicity, reactogenicity, and safety between a
QIV made by a new process wherein the thimerosal pre-
servative was added during the final formulation step,
and a TIV made by the already licensed method wherein
thimerosal was added early in the manufacturing process
(i.e. an historical control). However, our observations are




n (%; 95% CI) value (95% CI) value (95% CI)
18–60 years >60 years 18–60 years >60 years 18–60 years >60 years
N = 49 N = 70 N = 49 N = 70 N = 49 N = 70
A/H1N1 Day 0 35 37 39.2 15.2 – –
(71.4; 56.7–83.4) (52.9; 40.6–64.9) (24.0–63.8) (11.1–21.0)
Day 21 49 70 390.1 142.1 10.0 (6.3–15.7) 9.3 (6.8–12.8)
(100; 92.7–100) (100; 94.9–100) (293.8–518.1) (105.1–192.0)
A/H3N2 Day 0 26 38 14.1 13.0 – –
(53.1; 38.3–67.5) (54.3; 41.9–66.3) (10.1–19.8) (9.8–17.3)
Day 21 49 70 185.6 183.7 13.1 (9.3–18.5) 14.1 (10.2–19.5)
(100; 92.7–100) (100; 94.9–100) (140.9–244.5) (139.6–241.8)
B strain (Victoria) Day 0 34 58 22.7 28.0 – –
(69.4; 54.6–81.7) (82.9; 72.0–90.8) (15.2–34.0) (21.5–36.5)
Day 21 48 69 260.6 248.6 11.5 (7.0–18.7) 8.9 (6.3–12.4)
(98.0; 89.1–99.9) (98.6; 92.3–100) (184.6–368.0) (185.9–332.3)
TIV, inactivated trivalent influenza vaccine; Seropositive, titer ≥1:10; GMT, geometric mean titer; MGI, mean geometric increase defined as the geometric mean of
the ratio between pre-vaccination and post-vaccination reciprocal titers.
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based on a relatively limited sample size, and baseline
antibody titers differed between the TIV and QIV popu-
lations, particularly regarding the influenza B strains in
the older age group.
QIVs developed by GlaxoSmithKline Vaccines that
were approved in 2012–2013 in the US and Europe for
use in individuals aged ≥3 years are thimerosal-free for-
mulations provided as a single-dose pre-filled syringe.
However, GlaxoSmithKline Vaccines has developed a
multidose presentation of the QIV manufactured in
Quebec, Canada, for use in clinical settings where this
product is favored due to its reduced cost of acquisition
and cold storage [19]. Multidose vials must contain a
preservative to ensure sterility during the period when
multiple doses are withdrawn, and thimerosal is the pre-
ferred preservative. To harmonize the manufacturing
process of the QIV for thimerosal-free and thimerosal-
containing presentations, the addition of thimerosal to
product destined for filling in multidose vials was de-
layed to the terminal step of formulation. As this process
change could have affected the immunogenicity of the
product, we conducted the current study.
We confirmed that the QIV produced by the new
manufacturing process provided HI antibody responses
against all four vaccine strains which fulfilled all three li-
censure criteria for immunogenicity 21 days after vac-
cination in adults aged >60 years. In the 18–60 years
group, although all three licensure criteria where fulfilled
Table 5 Hemagglutination-inhibition antibody responses after TIV according to previous seasonal influenza






n/N (%; 95% CI) n/N (%; 95% CI) N; value (95% CI)
18–60 years >60 years 18–60 years >60 years 18–60 years >60 years
A/H1N1 Yes Day 0 13/20 19/44 – – – –
(65.0; 40.8–84.6) (43.2; 28.3–59.0)
Day 21 20/20 41/44 13/20 31/44 20; 7.1 44; 6.8
(100; 83.2–100) (93.2; 81.3–98.6) (65.0; 40.8–84.6) (70.5; 54.8–83.2) (3.5– 14.3) (4.7–9.8)
No Day 0 16/29 3/26 – – – –
(55.2; 35.7–73.6) (11.5; 2.4–30.2)
Day 21 29/29 21/26 22/29 19/26 29; 12.6 26; 16.0
(100; 88.1–100) (80.8; 60.6–93.4) (75.9; 56.5–89.7) (73.1; 52.2–88.4) (6.8– 23.3) (9.4–27.3)
A/H3N2 Yes Day 0 8/20 15/44 – – – –
(40.0; 19.1–63.9) (34.1; 20.5–49.9)
Day 21 20/20 43/44 15/20 35/44 20; 8.9 44; 9.9
(100; 83.2–100) (97.7; 88.0–99.9) (75.0; 50.9–91.3) (79.5; 64.7–90.2) (4.7– 16.8) (6.7–14.7)
No Day 0 7/29 2/26 – – – –
(24.1; 10.3–43.5) (7.7; 0.9–25.1)
Day 21 28/29 22/26 26/29 22/26 29; 17.2 26; 25.8
(96.6; 82.2–99.9) (84.6; 65.1–95.6) (89.7; 72.6–97.8) (84.6; 65.1–95.6) (11.8–25.1) (15.7–42.5)
B strain (Victoria) Yes Day 0 12/20 27/44 – –
(60.0; 36.1–80.9) (61.4; 45.5–75.6)
Day 21 20/20 44/44 10/20 27/44 20; 5.3 44; 5.0
(100; 83.2–100) (100; 92.0–100) (50.0; 27.2–72.8) (61.4; 45.5–75.6) (2.7– 10.4) (3.5–7.0)
No Day 0 9/29 8/26 – –
(31.0; 15.3–50.8) (30.8; 14.3–51.8)
Day 21 27/29 25/26 23/29 24/26 29; 19.6 26; 23.9
(93.1; 77.2–99.2) (96.2; 80.4–99.9) (79.3; 60.3–92.0) (92.3; 74.9–99.1) (10.3– 37.2) (14.0–40.6)
†Received (yes) or did not receive (no) seasonal influenza vaccine during the preceding 3 seasons (2009–2010, 2008–2009, 2007–2008); n/N, number fulfilling
definition of response/total number in group; TIV, inactivated trivalent influenza vaccine; SCR, seroconversion rate defined as the proportion with antibody titer
<1:10 at baseline and with post-vaccination titer of ≥1:40, or pre-vaccination titer of ≥1:10 and a ≥4-fold post-vaccination increase in titer; SPR, seroprotection rate
defined as proportion with post-vaccination titer ≥1:40; MGI, mean geometric increase defined as the geometric mean of the ratio between pre-vaccination and
post-vaccination reciprocal titers; Immune responses were assessed according to the to the European Union Committee for Medicinal Products for Human Use
(CHMP) licensure criteria: to fulfil the criteria the point estimates for SCR needed to be >40%, for SPR >70%, and MGI >2.5 in the 18–60 years group, and
SCR >30%, for SPR >60%, and MGI >2.0 in the >60 years group [21].
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against the influenza A strains and two of the criteria
were fulfilled for the B/Victoria and B/Yamagata strains,
seroconversion rates against both influenza B strains fell
below the licensure threshold, as would be expected
given the particularly high baseline GMTs against the in-
fluenza B strains. In the TIV study, HI antibody re-
sponses against each vaccine strain fulfilled all three
licensure criteria for immunogenicity in both age strata;
however, it should be noted that in this study cohort, the
baseline HI antibody titers against each vaccine strain
were lower than those in the QIV study cohort which
confounds a direct comparison.
Various studies have shown that pre-vaccination anti-
body titers influence HI antibody responses to seasonal
influenza vaccines, with lower responses to vaccination
reported among subjects with higher pre-vaccination ti-
ters derived from natural influenza infection or previous
influenza vaccination [22-26]. Moreover, a multivariate
analysis based on adults who received a TIV (Fluarix™)
showed that an age of ≥50 years, previous vaccination
within three years, and a pre-vaccination antibody titer
of ≥1:40 were predictive of a reduced response to vaccin-
ation [27]. To explore this phenomenon, we analyzed
antibody responses in subjects according to their previ-
ous vaccination history. In the QIV study, responses to
all of the QIV strains appeared reduced in younger sub-
jects who had received seasonal influenza vaccine during
the previous season compared with those who had not,
although this was not observed in older subjects. How-
ever, among younger previously vaccinated subjects,
GMTs at baseline against the influenza B strains were
relatively high. In the TIV study, there was a trend for
lower immune responses in the subjects who had re-
ceived seasonal vaccine at least once during the preced-
ing three seasons, and this trend was most pronounced
in the older group.
Overall, the immunogenicity results observed with the
thimerosal-containing QIV candidate were consistent
with those observed with the thimerosal-containing TIV,
and also with the immunogenicity results reported in a
previous pivotal Phase III randomized trial of thimerosal-
free QIV in adults [18]. In the previous trial, thimerosal-
free QIV was immunogenic for all four vaccine strains,
eliciting HI antibody responses which compared with
TIV were non-inferior for the shared strains and superior
for the additional B strain [18].
Pain was the most frequent injection site event, and
muscle aches, headache, and fatigue were the most fre-
quent solicited general events in both the QIV and TIV
studies, which was consistent with previous reports [18].
However, the incidence of pain was slightly higher in the
18–60 years groups than that previously observed, par-
ticularly among TIV recipients. The reason for the rela-
tively high occurrence of injection site pain is unknown,
Table 6 Solicited injection site and general adverse events during the 4-day post-vaccination periods in the total
vaccinated cohorts
TIV QIV
% (95% CI) % (95% CI)
18–60 years >60 years 18–60 years >60 years
N = 50 N = 69 N = 56 N = 56
Injection site events
Pain 82.0 (68.6–91.4) 26.1 (16.3–38.1) 73.2 (59.7–84.2) 33.9 (21.8–47.8)
Redness 0.0 (0.0–7.1) 0.0 (0.0–5.2) 1.8 (0.0–9.6) 0.0 (0.0–6.4)
Swelling 4.0 (0.5–13.7) 1.4 (0.0–7.8) 1.8 (0.0–9.6) 3.6 (0.4–12.3)
General events
Chest tightness 0.0 (0.0–7.1) 4.3 (0.9–12.2) 0.0 (0.0–6.4) 3.6 (0.4–12.3)
Chills 4.0 (0.5–13.7) 0.0 (0.0–5.2) 1.8 (0.0–9.6) 8.9 (3.0–19.6)
Cough 4.0 (0.5–13.7) 0.0 (0.0–5.2) 5.4 (1.1–14.9) 7.1 (2.0–17.3)
Fatigue 30.0 (17.9–44.6) 10.1 (4.2–19.8) 17.9 (8.9–30.4) 8.9 (3.0–19.6)
Headache 26.0 (14.6–40.3) 8.7 (3.3–18.0) 19.6 (10.2–32.4) 8.9 (3.0–19.6)
Joint pain at other location 12.0 (4.5–24.3) 4.3 (0.9–12.2) 12.5 (5.2–24.1) 5.4 (1.1–14.9)
Muscle pain 34.0 (21.2–48.8) 8.7 (3.3–18.0) 37.5 (24.9–51.5) 10.7 (4.0–21.9)
Red eyes 8.0 (2.2–19.2) 1.4 (0.0–7.8) 5.4 (1.1–14.9) 0.0 (0.0–6.4)
Sore throat 16.0 (7.2–29.1) 2.9 (0.4–10.1) 12.5 (5.2–24.1) 8.9 (3.0–19.6)
Swelling of the face 2.0 (0.1–10.6) 0.0 (0.0–5.2) 0.0 (0.0–6.4) 0.0 (0.0–6.4)
Increased temperature 2.0 (0.1–10.6) 1.4 (0.0–7.8) 0.0 (0.0–6.4) 0.0 (0.0–6.4)
TIV, inactivated trivalent influenza vaccine; QIV, inactivated quadrivalent influenza vaccine.
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although there were no reports of Grade 3 pain, and all
events were mild or moderate in intensity and resolved
within four days in the vast majority of subjects.
Conclusions
In a non-randomized study, we showed that a thimerosal-
containing QIV candidate was immunogenic in adults
and elderly adults. The reactogenicity profile of the QIV
candidate was consistent with the established profile of
TIV, and no safety concerns were raised. These results
support acceptability of a manufacturing process change
in which the thimerosal is added as a preservative at the
point at which batches are filled into multidose vials.
Abbreviations
AE: Adverse events; CHMP: European Union Committee for Medicinal
Products for Human Use; CI: Confidence interval; HI: Hemagglutination
inhibition; GMT: Geometric mean titre; MedDRA: Medical Dictionary for
Regulatory Activities; MGI: Mean geometric increase; SAE: Serious adverse
events; SCR: Seroconversion rate; SPR: Seroprotection rate; TIV: Inactivated
trivalent influenza vaccines; QIV: Inactivated quadrivalent influenza vaccines;
WHO: World Health Organization.
Competing interests
VK Jain, V Chandrasekaran, L Wang, P Li, A Liu and BL Innis are employees of
the GlaxoSmithKline group of companies. VK Jain, P Li, A Liu, L Wang, and BL
Innis report ownership of stock options and/or restricted shares.
Authors’ contributions
All authors participated in the design or implementation or analysis, and
interpretation of the study; and the development of this manuscript. All
authors had full access to the data and gave final approval before
submission. VKJ, LW, AL and BLI managed the study at GlaxoSmithKline
Vaccines. VC and PL were responsible for the statistical input.
Acknowledgements
The authors thank the study participants for their participation in this study.
They also thank G Girard, the principal investigator, and her clinical teams for
their contribution to the study and their support and care of participants. We
are grateful to all teams of GSK Biologicals for their contribution to this
study, especially L Fries for clinical development, P Boutet for project
management, V Dodeur for clinical data coordination, B Merckx and K
Peeters for study management, R Ippersiel and S Ravault (Regulatory affairs
representative), X Druart (Scientific Writer) and W Dewé for franchise
statistics. Finally, the authors thank A Moon (Moon Medical Communications
Ltd, UK) for providing medical writing services and B Dumont (Business and
Decision Life Sciences, on behalf of GlaxoSmithKline Vaccines) for editorial
assistance and manuscript coordination.
Financial disclosure
GlaxoSmithKline Biologicals SA was the funding source and was involved in
all stages of the study conduct and analysis (ClinicalTrials.gov Identifier:
NCT01440387; NCT01153685). GlaxoSmithKline Biologicals SA also took in
charge all costs associated with the development and the publishing of the
present manuscript. All authors had full access to the data and the
corresponding author had final responsibility to submit for publication.
Trademark ownership
FluLaval™, FluLaval™ Quadrivalent, and Fluviral™ are trademarks of the
GlaxoSmithKline group of companies.
Received: 21 October 2013 Accepted: 14 February 2014
Published: 10 March 2014
References
1. Li S, Leader S: Economic burden and absenteeism from influenza-like
illness in healthy households with children (5–17 years) in the US.
Respir Med 2007, 101(6):1244–1250.
2. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley
PM, Weintraub E, Bridges CB: The annual impact of seasonal influenza
in the US: measuring disease burden and costs. Vaccine 2007,
25(27):5086–5096.
3. Nichol KL, D’Heilly SJ, Greenberg ME, Ehlinger E: Burden of influenza-like
illness and effectiveness of influenza vaccination among working adults
aged 50–64 years. Clin Infect Dis 2009, 48(3):292–298.
4. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E: Effectiveness of
influenza vaccine in the community-dwelling elderly. N Engl J Med 2007,
357(14):1373–1381.
5. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ,
Fukuda K: Influenza-associated hospitalizations in the United States.
JAMA 2004, 292(11):1333–1340.
6. Advisory Committee on Immunization Practices: CDC’s Advisory Committee
on Immunization Practices (ACIP) Recommends Universal Annual Influenza
Vaccination. 2010. Press Release; http://www.cdc.gov/media/pressrel/2010/
r100224.htm. [Accessed 11 October 2013]
7. United States Centers for Disease Control and Prevention: Seasonal influenza
activity surveillance reports: 2000–2001 to 2010–2011 seasons. http://www.cdc.
gov/flu/weekly/pastreports.htm. [Accessed 11 October 2013]
8. WHO Writing Group, Ampofo WK, Baylor N, Cobey S, Cox NJ, Daves S,
Edwards S, Ferguson N, Grohmann G, Hay A, Katz J, Kullabutr K, Lambert L,
Levandowski R, Mishra AC, Monto A, Siqueira M, Tashiro M, Waddell AL,
Wairagkar N, Wood J, Zambon M, Zhang W: Improving influenza vaccine
virus selection: report of a WHO informal consultation held at WHO
headquarters, Geneva, Switzerland, 14–16 June 2010. Influenza Other
Respi Viruses 2012, 6(2):142–152. e141-145.
9. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A,
Lindstrom S, Shay DK: Effectiveness of inactivated influenza
vaccines varied substantially with antigenic match from the
2004–2005 season to the 2006–2007 season. J Infect Dis 2009,
199(2):159–167.
10. Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X: Efficacy of live
attenuated influenza vaccine in children against influenza B viruses by
lineage and antigenic similarity. Vaccine 2010, 28(9):2149–2156.
11. Lo YC, Chuang JH, Kuo HW, Huang WT, Hsu YF, Liu MT, Chen CH, Huang
HH, Chang CH, Chou JH, Chang FY, Lin TY, Chiu WT: Surveillance and
vaccine effectiveness of an influenza epidemic predominated by
vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan,
2011–12 season. PLoS ONE 2013, 8(3):e58222.
12. World Health Organization: Recommended composition of influenza virus
vaccines for use in the 2012–2013 northern hemisphere influenza season. 2012.
http://www.who.int/influenza/vaccines/virus/recommendations/
201202_recommendation.pdf. [Accessed 11 October 2013]
13. Fluarix™ Quadrivalent (influenza virus vaccine): Prescribing Information.
GlaxoSmithKline Biologicals, Rixensart, Belgium. 2013. http://www.fda.gov/
downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/
UCM220624.pdf. [Accessed 2 January 2014]
14. Flulaval™ Quadrivalent (influenza virus vaccine): Prescribing Information.
GlaxoSmithKline, Research Triangle Park, NC 27709, USA. 2013. http://www.fda.
gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/
UCM366070.pdf. [Accessed 2 January 2014]
15. Flumist® Quadrivalent (Influenza Vaccine Live I: Prescribing Information.
MedImmune LLC, Gaithersburg, MD 20878, USA. 2013. http://www.fda.gov/
BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm293952.htm.
[Accessed 2 January 2014]
16. Fluzone™ Quadrivalent (influenza virus vaccine): Prescribing Information.
Sanofi Pasteur Inc. 1 Swiftwater, PA 18370, USA. 2013. http://www.fda.gov/
downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/
UCM356094.pdf. [Accessed 2 January 2014]
17. Langley JM, Carmona Martinez A, Chatterjee A, Halperin SA, McNeil S,
Reisinger KS, Aggarwal N, Huang LM, Peng CT, Garcia-Sicilia J, De la
Cueva S, Cabañas F, Treviño-Garza C, Rodríguez-Weber MA, de la OM,
Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK: Immunogenicity and
safety of an inactivated quadrivalent influenza vaccine candidate: a
phase III randomized controlled trial in children. J Infect Dis 2013,
208(4):544–553.
Jain et al. BMC Infectious Diseases 2014, 14:133 Page 11 of 12
http://www.biomedcentral.com/1471-2334/14/133
18. Tinoco C, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V,
Dewé W, Liu A, Innis B, Jain V: Immunogenicity, reactogenicity, and
safety of quadrivalent inactivated influenza vaccine versus trivalent
inactivated influenza vaccine in healthy adults aged ≥18 years: a phase
III, randomized trial. Vaccine 2013. In press.
19. World Health Organization: Meeting of the Strategic Advisory Group of
Experts on Immunization, April 2012 – conclusions and
recommendations. Information on vaccines for an Intergovernmental
Negotiating Committee to prepare a global legally binding instrument
on the use of mercury. Wkly Epidemiol Rec 2012, 21(87):201–216.
20. Hehme N, Künzel W, Petschke F, Türk G, Raderecht C, van Hoecke C, Sänger
R: Ten years of experience with the trivalent split-influenza vaccine,
Fluarix™. Clin Drug Investig 2002, 22(11):751–769.
21. The European Agency for the Evaluation of Medicinal Products Committee
for Proprietary Medicinal Products: Note for guidance on harmonization of




22. Govaert TM, Sprenger MJ, Dinant GJ, Aretz K, Masurel N, Knottnerus JA:
Immune response to influenza vaccination of elderly people. A
randomized double-blind placebo-controlled trial. Vaccine 1994,
12(13):1185–1189.
23. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA: The
efficacy of influenza vaccination in elderly individuals. A randomized
double-blind placebo-controlled trial. JAMA 1994, 272(21):1661–1665.
24. Iorio AM, Camilloni B, Basileo M, Neri M, Lepri E, Spighi M: Effects of
repeated annual influenza vaccination on antibody responses against
unchanged vaccine antigens in elderly frail institutionalized volunteers.
Gerontology 2007, 53(6):411–418.
25. Nabeshima S, Kashiwagi K, Murata M, Kanamoto Y, Furusyo N, Hayashi J:
Antibody response to influenza vaccine in adults vaccinated with
identical vaccine strains in consecutive years. J Med Virol 2007,
79(3):320–325.
26. Pyhala R, Kumpulainen V, Alanko S, Forsten T: HI antibody kinetics in adult
volunteers immunized repeatedly with inactivated trivalent influenza
vaccine in 1990–1992. Vaccine 1994, 12(10):947–952.
27. Treanor JJ, Campbell JD, Brady RC, Keitel WA, Drame M, Jain VK, Innis BL:
Rapid licensure of a new, inactivated influenza vaccine in the United
States. Hum Vaccin 2005, 1(6):239–244.
doi:10.1186/1471-2334-14-133
Cite this article as: Jain et al.: A historically-controlled Phase III study in
adults to characterize the acceptability of a process change for
manufacturing inactivated quadrivalent influenza vaccine. BMC Infectious
Diseases 2014 14:133.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Jain et al. BMC Infectious Diseases 2014, 14:133 Page 12 of 12
http://www.biomedcentral.com/1471-2334/14/133
